메뉴 건너뛰기




Volumn 66, Issue 3, 2012, Pages 270-280

New lipid-lowering drugs: An update

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ATORVASTATIN; AVASIMIBE; BILE ACID SEQUESTRANT; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESEVELAM; EPROTIROME; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAPAQUISTAT; LAROPIPRANT; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRANSFER PROTEIN INHIBITOR; NCX 6560; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHOLIPASE INHIBITOR; PITIVASTATIN; PPD 10558; ROSUVASTATIN; SOBETIROME; SQUALENE SYNTHASE INHIBITOR; THYROMIMETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

EID: 84857351347     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02867.x     Document Type: Review
Times cited : (61)

References (133)
  • 1
    • 0000730344 scopus 로고    scopus 로고
    • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP)
    • Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
    • Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001; 285 (19): 2486-97.
    • (2001) JAMA , vol.285 , Issue.19 , pp. 2486-2497
  • 2
    • 33644810298 scopus 로고    scopus 로고
    • JBS 2: The Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice
    • British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association.
    • British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl. V): v1-52.
    • (2005) Heart , vol.91 , Issue.SUPPL. V
  • 3
    • 34748924577 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
    • DOI 10.1016/j.atherosclerosis.2007.08.024, PII S002191500700528X
    • Graham I, Atar D, Borch-Johnsen K, et al., European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007; 194 (1): 1-45. (Pubitemid 47470068)
    • (2007) Atherosclerosis , vol.194 , Issue.1 , pp. 1-45
    • Graham, I.1
  • 4
    • 77955505564 scopus 로고    scopus 로고
    • Biological, clinical and population relevance of 95 loci for blood lipids
    • Teslovich TM, Musunuru K, Smith AV, et al., Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466 (7307): 707-13.
    • (2010) Nature , vol.466 , Issue.7307 , pp. 707-713
    • Teslovich, T.M.1    Musunuru, K.2    Smith, A.V.3
  • 5
    • 0037099364 scopus 로고    scopus 로고
    • The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations
    • DOI 10.1016/S0002-9149(02)02436-0, PII S0002914902024360
    • Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90 (2): 139-43. (Pubitemid 34775122)
    • (2002) American Journal of Cardiology , vol.90 , Issue.2 , pp. 139-143
    • Sacks, F.M.1
  • 6
    • 38349050019 scopus 로고    scopus 로고
    • The Emerging Risk Factors Collaboration: Analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases
    • Danesh J, Erqou S, Walker M, et al., The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 2007; 22 (12): 839-69.
    • (2007) Eur J Epidemiol , vol.22 , Issue.12 , pp. 839-869
    • Danesh, J.1    Erqou, S.2    Walker, M.3
  • 7
    • 33846637379 scopus 로고    scopus 로고
    • Triglycerides and the risk of coronary heart disease: 10 158 Incident cases among 262 525 participants in 29 Western prospective studies
    • DOI 10.1161/CIRCULATIONAHA.106.637793, PII 0000301720070130000007
    • Sarwar N, Danesh J, Eiriksdottir G, et al., Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115 (4): 450-8. (Pubitemid 46184196)
    • (2007) Circulation , vol.115 , Issue.4 , pp. 450-458
    • Sarwar, N.1    Danesh, J.2    Eiriksdottir, G.3    Sigurdsson, G.4    Wareham, N.5    Bingham, S.6    Boekholdt, S.M.7    Khaw, K.-T.8    Gudnason, V.9
  • 8
    • 79958148945 scopus 로고    scopus 로고
    • Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management
    • Chapman MJ, Ginsberg HN, Amarenco P, et al., Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32 (11): 1345-61.
    • (2011) Eur Heart J , vol.32 , Issue.11 , pp. 1345-1361
    • Chapman, M.J.1    Ginsberg, H.N.2    Amarenco, P.3
  • 9
    • 56349154187 scopus 로고    scopus 로고
    • The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia
    • Fruchart JC, Sacks F, Hermans MP, et al., The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102 (10 Suppl.): 1K-34K.
    • (2008) Am J Cardiol , vol.102 , Issue.10 SUPPL.
    • Fruchart, J.C.1    Sacks, F.2    Hermans, M.P.3
  • 10
    • 7744243517 scopus 로고    scopus 로고
    • Lipid-altering agents: The future
    • DOI 10.1111/j.1742-1241.2004.00087.x
    • Wierzbicki AS. Lipid-altering agents: the future. Int J Clin Pract 2004; 58 (11): 1063-72. (Pubitemid 39642422)
    • (2004) International Journal of Clinical Practice , vol.58 , Issue.11 , pp. 1063-1072
    • Wierzbicki, A.S.1
  • 11
    • 0038201555 scopus 로고    scopus 로고
    • The lipid and non-lipid effects of statins
    • DOI 10.1016/S0163-7258(03)00055-X
    • Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99 (1): 95-112. (Pubitemid 36694752)
    • (2003) Pharmacology and Therapeutics , vol.99 , Issue.1 , pp. 95-112
    • Wierzbicki, A.S.1    Poston, R.2    Ferro, A.3
  • 12
    • 82555168428 scopus 로고    scopus 로고
    • Effect of two intensive statin regimens on progression of coronary disease
    • Nicholls SJ, Ballantyne CM, Barter PJ, et al., Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365 (22): 2078-87.
    • (2011) N Engl J Med , vol.365 , Issue.22 , pp. 2078-2087
    • Nicholls, S.J.1    Ballantyne, C.M.2    Barter, P.J.3
  • 13
    • 79960823316 scopus 로고    scopus 로고
    • Comparison of preventive effect on cardiovascular events with different statins - The CIRCLE study
    • Maruyama T, Takada M, Nishibori Y, et al., Comparison of preventive effect on cardiovascular events with different statins-The CIRCLE study. Circ J 2011; 75 (8): 1951-9.
    • (2011) Circ J , vol.75 , Issue.8 , pp. 1951-1959
    • Maruyama, T.1    Takada, M.2    Nishibori, Y.3
  • 14
    • 84861414922 scopus 로고    scopus 로고
    • NCX 6560, a novel nitric oxide donating atorvastatin with a promising safety and efficacy profile: A randomised, double blind placebo and active control study
    • A14267 [abstract].
    • Djian JP, Maucci R, Guilmin L, Ferreira T, Pfister P. NCX 6560, a novel nitric oxide donating atorvastatin with a promising safety and efficacy profile: A randomised, double blind placebo and active control study. Circulation 2010; 122 (21 Suppl.): A14267 [abstract].
    • (2010) Circulation , vol.122 , Issue.21 SUPPL.
    • Djian, J.P.1    Maucci, R.2    Guilmin, L.3    Ferreira, T.4    Pfister, P.5
  • 16
    • 77952708442 scopus 로고    scopus 로고
    • Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis
    • Jun M, Foote C, Lv J, et al., Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375 (9729): 1875-84.
    • (2010) Lancet , vol.375 , Issue.9729 , pp. 1875-1884
    • Jun, M.1    Foote, C.2    Lv, J.3
  • 17
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • Ginsberg HN, Elam MB, Lovato LC, et al., Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362 (17): 1563-74.
    • (2010) N Engl J Med , vol.362 , Issue.17 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 18
    • 77954921239 scopus 로고    scopus 로고
    • Fibrates: No ACCORD on their use in the treatment of dyslipidaemia
    • Wierzbicki AS. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Curr Opin Lipidol 2010; 21 (4): 352-8.
    • (2010) Curr Opin Lipidol , vol.21 , Issue.4 , pp. 352-358
    • Wierzbicki, A.S.1
  • 20
    • 47649113235 scopus 로고    scopus 로고
    • Colesevelam hydrochloride: A specifically engineered bile acid sequestrant
    • DOI 10.2217/17460875.3.3.237
    • Manghat P, Wierzbicki AS. Colesevelam-a specifically engineered bile acid sequestrant. Fut Lipidol 2008; 3 (3): 237-55. (Pubitemid 352015399)
    • (2008) Future Lipidology , vol.3 , Issue.3 , pp. 237-255
    • Manghat, P.1    Wierzbicki, A.S.2
  • 21
    • 79952767350 scopus 로고    scopus 로고
    • Niacin: The only vitamin that reduces cardiovascular events
    • Wierzbicki AS. Niacin: the only vitamin that reduces cardiovascular events. Int J Clin Pract 2011; 65 (4): 379-85.
    • (2011) Int J Clin Pract , vol.65 , Issue.4 , pp. 379-385
    • Wierzbicki, A.S.1
  • 22
    • 0016630250 scopus 로고
    • Clofibrate and niacin in coronary heart disease
    • The Coronary Drug Project Research Group.
    • The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231 (4): 360-81.
    • (1975) JAMA , vol.231 , Issue.4 , pp. 360-381
  • 23
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • AIM-HIGH investigators. in press.
    • AIM-HIGH investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, in press.
    • (2011) N Engl J Med
  • 24
    • 84857250961 scopus 로고    scopus 로고
    • A randomized trial of the long-term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant
    • HPS2-THRIVE investigators ClinicalTrials gov. 2 February. NCT00461630. (accessed 10 October 2011)
    • HPS2-THRIVE investigators. A randomized trial of the long-term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant. Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). ClinicalTrials gov. 2 February 2009. NCT00461630. (accessed 10 October 2011).
    • (2009) Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)
  • 26
    • 67649961784 scopus 로고    scopus 로고
    • Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: A new therapeutic approach to treatment of hypercholesterolemia
    • Seiki S, Frishman WH. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. Cardiol Rev 2009; 17 (2): 70-6.
    • (2009) Cardiol Rev , vol.17 , Issue.2 , pp. 70-76
    • Seiki, S.1    Frishman, W.H.2
  • 27
    • 79955762929 scopus 로고    scopus 로고
    • Lapaquistat acetate: Development of a squalene synthase inhibitor for the treatment of hypercholesterolemia
    • Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation 2011; 123 (18): 1974-85.
    • (2011) Circulation , vol.123 , Issue.18 , pp. 1974-1985
    • Stein, E.A.1    Bays, H.2    O'Brien, D.3    Pedicano, J.4    Piper, E.5    Spezzi, A.6
  • 28
    • 69149090880 scopus 로고    scopus 로고
    • Future challenges for microsomal transport protein inhibitors
    • Wierzbicki AS, Hardman T, Prince WT. Future challenges for microsomal transport protein inhibitors. Curr Vasc Pharmacol 2009; 7 (3): 277-86.
    • (2009) Curr Vasc Pharmacol , vol.7 , Issue.3 , pp. 277-286
    • Wierzbicki, A.S.1    Hardman, T.2    Prince, W.T.3
  • 30
    • 48349088178 scopus 로고    scopus 로고
    • Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
    • Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5 (8): 497-505.
    • (2008) Nat Clin Pract Cardiovasc Med , vol.5 , Issue.8 , pp. 497-505
    • Samaha, F.F.1    McKenney, J.2    Bloedon, L.T.3    Sasiela, W.J.4    Rader, D.J.5
  • 31
    • 0036470894 scopus 로고    scopus 로고
    • Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: Cholesterol acyltransferase (ACAT) inhibitor
    • DOI 10.1016/S0006-2952(01)00918-2, PII S0006295201009182
    • Taghibiglou C, Van Iderstine SC, Kulinski A, Rudy D, Adeli K. Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor. Biochem Pharmacol 2002; 63 (3): 349-60. (Pubitemid 34169715)
    • (2002) Biochemical Pharmacology , vol.63 , Issue.3 , pp. 349-360
    • Taghibiglou, C.1    Van Iderstine, S.C.2    Kulinski, A.3    Rudy, D.4    Adeli, K.5
  • 33
    • 33645097996 scopus 로고    scopus 로고
    • Effect of ACAT inhibition on the progression of coronary atherosclerosis
    • Nissen SE, Tuzcu EM, Brewer HB, et al., Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006; 354 (12): 1253-63.
    • (2006) N Engl J Med , vol.354 , Issue.12 , pp. 1253-1263
    • Nissen, S.E.1    Tuzcu, E.M.2    Brewer, H.B.3
  • 34
    • 62649118779 scopus 로고    scopus 로고
    • ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: The CAPTIVATE randomized trial
    • Meuwese MC, de GE, Duivenvoorden R, et al., ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 2009; 301 (11): 1131-9.
    • (2009) JAMA , vol.301 , Issue.11 , pp. 1131-1139
    • Meuwese, M.C.1    De, G.E.2    Duivenvoorden, R.3
  • 35
    • 77958459353 scopus 로고    scopus 로고
    • A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice
    • Yoshinaka Y, Shibata H, Kobayashi H, et al., A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice. Atherosclerosis 2010; 213 (1): 85-91.
    • (2010) Atherosclerosis , vol.213 , Issue.1 , pp. 85-91
    • Yoshinaka, Y.1    Shibata, H.2    Kobayashi, H.3
  • 36
    • 0023001772 scopus 로고
    • Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
    • Canner PL, Berge KG, Wenger NK, et al., Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8 (6): 1245-55. (Pubitemid 17208898)
    • (1986) Journal of the American College of Cardiology , vol.8 , Issue.6 , pp. 1245-1255
    • Canner, P.L.1    Berge, K.G.2    Wenger, N.K.3
  • 37
    • 9744228694 scopus 로고    scopus 로고
    • Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: Past, present and future prospects
    • DOI 10.1016/j.yjmcc.2004.09.013, PII S0022282804002846
    • Morkin E, Ladenson P, Goldman S, Adamson C. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 2004; 37 (6): 1137-46. (Pubitemid 39585161)
    • (2004) Journal of Molecular and Cellular Cardiology , vol.37 , Issue.6 , pp. 1137-1146
    • Morkin, E.1    Ladenson, P.2    Goldman, S.3    Adamson, C.4
  • 38
    • 77949349469 scopus 로고    scopus 로고
    • Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia
    • Ladenson PW, Kristensen JD, Ridgway EC, et al., Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362 (10): 906-16.
    • (2010) N Engl J Med , vol.362 , Issue.10 , pp. 906-916
    • Ladenson, P.W.1    Kristensen, J.D.2    Ridgway, E.C.3
  • 40
    • 79958229126 scopus 로고    scopus 로고
    • Lipoprotein(a): Medical treatment options for an elusive molecule
    • Parhofer KG. Lipoprotein(a): medical treatment options for an elusive molecule. Curr Pharm Des 2011; 17 (9): 871-6.
    • (2011) Curr Pharm des , vol.17 , Issue.9 , pp. 871-876
    • Parhofer, K.G.1
  • 41
    • 0031055810 scopus 로고    scopus 로고
    • Not nonsense but antisense - Applications of antisense oligonucleotides in different fields of medicine
    • Oberbauer R. Not nonsense but antisense-applications of antisense oligonucleotides in different fields of medicine. Wien Klin Wochenschr 1997; 109 (2): 40-6. (Pubitemid 27081119)
    • (1997) Wiener Klinische Wochenschrift , vol.109 , Issue.2 , pp. 40-46
    • Oberbauer, R.1
  • 42
    • 78649877710 scopus 로고    scopus 로고
    • Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
    • Straarup EM, Fisker N, Hedtjarn M, et al., Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 2010; 38 (20): 7100-11.
    • (2010) Nucleic Acids Res , vol.38 , Issue.20 , pp. 7100-7111
    • Straarup, E.M.1    Fisker, N.2    Hedtjarn, M.3
  • 44
    • 33750207033 scopus 로고    scopus 로고
    • Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
    • DOI 10.1161/CIRCULATIONAHA.105.606442, PII 0000301720061017000012
    • Kastelein JJ, Wedel MK, Baker BF, et al., Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114 (16): 1729-35. (Pubitemid 44607121)
    • (2006) Circulation , vol.114 , Issue.16 , pp. 1729-1735
    • Kastelein, J.J.P.1    Wedel, M.K.2    Baker, B.F.3    Su, J.4    Bradley, J.D.5    Yu, R.Z.6    Chuang, E.7    Graham, M.J.8    Crooke, R.M.9
  • 45
    • 79959661095 scopus 로고    scopus 로고
    • Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
    • in press.
    • Akdim F, Tribble DL, Flaim JD, et al., Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011, in press.
    • (2011) Eur Heart J
    • Akdim, F.1    Tribble, D.L.2    Flaim, J.D.3
  • 46
    • 77949485460 scopus 로고    scopus 로고
    • Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial
    • Raal FJ, Santos RD, Blom DJ, et al., Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375 (9719): 998-1006.
    • (2010) Lancet , vol.375 , Issue.9719 , pp. 998-1006
    • Raal, F.J.1    Santos, R.D.2    Blom, D.J.3
  • 47
    • 77951072532 scopus 로고    scopus 로고
    • Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
    • Visser ME, Akdim F, Tribble DL, et al., Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010; 51 (5): 1057-62.
    • (2010) J Lipid Res , vol.51 , Issue.5 , pp. 1057-1062
    • Visser, M.E.1    Akdim, F.2    Tribble, D.L.3
  • 48
    • 83555166075 scopus 로고    scopus 로고
    • ApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (Fatp5)
    • Ason B, Castro-Perez J, Tep S, et al., ApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (Fatp5). Lipids 2011; 46 (11): 991-1003.
    • (2011) Lipids , vol.46 , Issue.11 , pp. 991-1003
    • Ason, B.1    Castro-Perez, J.2    Tep, S.3
  • 49
    • 79953885803 scopus 로고    scopus 로고
    • Hypobetalipoproteinemia: Genetics, biochemistry, and clinical spectrum
    • Tarugi P, Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Adv Clin Chem 2011; 54: 81-107.
    • (2011) Adv Clin Chem , vol.54 , pp. 81-107
    • Tarugi, P.1    Averna, M.2
  • 50
    • 5444267382 scopus 로고    scopus 로고
    • Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia
    • DOI 10.1016/j.atherosclerosis.2004.06.011, PII S0021915004003648
    • Cohn JS, Tremblay M, Batal R, et al., Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis 2004; 177 (1): 137-45. (Pubitemid 39361148)
    • (2004) Atherosclerosis , vol.177 , Issue.1 , pp. 137-145
    • Cohn, J.S.1    Tremblay, M.2    Batal, R.3    Jacques, H.4    Rodriguez, C.5    Steiner, G.6    Mamer, O.7    Davignon, J.8
  • 51
    • 79960602485 scopus 로고    scopus 로고
    • Lowering apolipoprotein CIII delays onset of type 1 diabetes
    • Holmberg R, Refai E, Hoog A, et al., Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci USA 2011; 108 (26): 10685-9.
    • (2011) Proc Natl Acad Sci USA , vol.108 , Issue.26 , pp. 10685-10689
    • Holmberg, R.1    Refai, E.2    Hoog, A.3
  • 52
    • 80053961826 scopus 로고    scopus 로고
    • Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
    • Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011; 21 (11): 835-43.
    • (2011) Nutr Metab Cardiovasc Dis , vol.21 , Issue.11 , pp. 835-843
    • Tibolla, G.1    Norata, G.D.2    Artali, R.3    Meneghetti, F.4    Catapano, A.L.5
  • 53
    • 33645103550 scopus 로고    scopus 로고
    • Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    • Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354 (12): 1264-72.
    • (2006) N Engl J Med , vol.354 , Issue.12 , pp. 1264-1272
    • Cohen, J.C.1    Boerwinkle, E.2    Mosley, Jr.T.H.3    Hobbs, H.H.4
  • 54
    • 73849114174 scopus 로고    scopus 로고
    • PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia
    • Cariou B, Ouguerram K, Zair Y, et al., PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009; 29 (12): 2191-7.
    • (2009) Arterioscler Thromb Vasc Biol , vol.29 , Issue.12 , pp. 2191-2197
    • Cariou, B.1    Ouguerram, K.2    Zair, Y.3
  • 55
    • 69549138572 scopus 로고    scopus 로고
    • Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents
    • Baass A, Dubuc G, Tremblay M, et al., Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009; 55 (9): 1637-45.
    • (2009) Clin Chem , vol.55 , Issue.9 , pp. 1637-1645
    • Baass, A.1    Dubuc, G.2    Tremblay, M.3
  • 57
    • 70350389729 scopus 로고    scopus 로고
    • Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine
    • Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009; 284 (42): 28885-95.
    • (2009) J Biol Chem , vol.284 , Issue.42 , pp. 28885-28895
    • Li, H.1    Dong, B.2    Park, S.W.3    Lee, H.S.4    Chen, W.5    Liu, J.6
  • 58
    • 34447299120 scopus 로고    scopus 로고
    • The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
    • DOI 10.1016/j.atherosclerosis.2006.08.039, PII S0021915006005223
    • Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007; 193 (2): 445-8. (Pubitemid 47058112)
    • (2007) Atherosclerosis , vol.193 , Issue.2 , pp. 445-448
    • Hooper, A.J.1    Marais, A.D.2    Tanyanyiwa, D.M.3    Burnett, J.R.4
  • 59
    • 77649274263 scopus 로고    scopus 로고
    • PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
    • Mbikay M, Sirois F, Mayne J, et al., PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010; 584 (4): 701-6.
    • (2010) FEBS Lett , vol.584 , Issue.4 , pp. 701-706
    • Mbikay, M.1    Sirois, F.2    Mayne, J.3
  • 60
    • 64849093564 scopus 로고    scopus 로고
    • Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
    • Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J 2009; 419 (3): 577-84.
    • (2009) Biochem J , vol.419 , Issue.3 , pp. 577-584
    • Duff, C.J.1    Scott, M.J.2    Kirby, I.T.3    Hutchinson, S.E.4    Martin, S.L.5    Hooper, N.M.6
  • 61
    • 84862161906 scopus 로고    scopus 로고
    • Safety, lipid, and lipoprotein effects of REGN727/SAR236553, a fully-human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody administered intravenously to healthy volunteers
    • A2325 [abstract].
    • Swergold G, Biedermann S, Renard R, Nadler D, Wu R, Mellis S. Safety, lipid, and lipoprotein effects of REGN727/SAR236553, a fully-human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody administered intravenously to healthy volunteers. Circulation 2010; 122 (21 Suppl.): A2325 [abstract].
    • (2010) Circulation , vol.122 , Issue.21 SUPPL.
    • Swergold, G.1    Biedermann, S.2    Renard, R.3    Nadler, D.4    Wu, R.5    Mellis, S.6
  • 63
    • 50149101511 scopus 로고    scopus 로고
    • Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
    • Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al., Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008; 105 (33): 11915-20.
    • (2008) Proc Natl Acad Sci USA , vol.105 , Issue.33 , pp. 11915-11920
    • Frank-Kamenetsky, M.1    Grefhorst, A.2    Anderson, N.N.3
  • 64
    • 84857251001 scopus 로고    scopus 로고
    • Inhibition of proprotein convertase subtilisin/kexin type 9 with a monoclonal antibody REGN727/SAR236553, effectively reduces low-density- lipoprotein cholesterol, as mono or add-on therapy in heterozygous familial and non familial hypercholesterolemia
    • [abstract].
    • Swergold G, Smith W, Mellis S, et al., Inhibition of proprotein convertase subtilisin/kexin type 9 with a monoclonal antibody REGN727/SAR236553, effectively reduces low-density-lipoprotein cholesterol, as mono or add-on therapy in heterozygous familial and non familial hypercholesterolemia. Circulation 2011; 124 (21 Suppl.): A16265 [abstract].
    • (2011) Circulation , vol.124 , Issue.21 SUPPL.
    • Swergold, G.1    Smith, W.2    Mellis, S.3
  • 65
    • 84857252177 scopus 로고    scopus 로고
    • A Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability and pharmacodynamics of AMG145
    • A10701 [abstract].
    • Dias C, Shaywitz A, Smith B, et al., A Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability and pharmacodynamics of AMG145. Circulation 2011; 124 (21 Suppl.): A10701 [abstract].
    • (2011) Circulation , vol.124 , Issue.21 SUPPL.
    • Dias, C.1    Shaywitz, A.2    Smith, B.3
  • 66
    • 0032894986 scopus 로고    scopus 로고
    • Cholesterol reduction by different plant stanol mixtures and with variable fat intake
    • DOI 10.1016/S0026-0495(99)90053-7
    • Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism 1999; 48 (5): 575-80. (Pubitemid 29230516)
    • (1999) Metabolism: Clinical and Experimental , vol.48 , Issue.5 , pp. 575-580
    • Gylling, H.1    Miettinen, T.A.2
  • 68
    • 81755174287 scopus 로고    scopus 로고
    • The ezetimibe Jonah: The trials and tribulations of an unlucky drug
    • Wierzbicki AS. The ezetimibe Jonah: the trials and tribulations of an unlucky drug. Int J Clin Pract 2011; 65 (12): 1207-8.
    • (2011) Int J Clin Pract , vol.65 , Issue.12 , pp. 1207-1208
    • Wierzbicki, A.S.1
  • 69
    • 47149083828 scopus 로고    scopus 로고
    • A fishy business: Omega-3 fatty acids and cardiovascular disease
    • DOI 10.1111/j.1742-1241.2008.01781.x
    • Wierzbicki AS. A fishy business: omega-3 fatty acids and cardiovascular disease. Int J Clin Pract 2008; 62 (8): 1142-6. (Pubitemid 351977613)
    • (2008) International Journal of Clinical Practice , vol.62 , Issue.8 , pp. 1142-1146
    • Wierzbicki, A.S.1
  • 70
    • 0345109256 scopus 로고    scopus 로고
    • Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: Results of the GISSI-Prevenzione trial
    • Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
    • Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354 (9177): 447-55.
    • (1999) Lancet , vol.354 , Issue.9177 , pp. 447-455
  • 72
    • 80051784104 scopus 로고    scopus 로고
    • Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)
    • Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108 (5): 682-90.
    • (2011) Am J Cardiol , vol.108 , Issue.5 , pp. 682-690
    • Bays, H.E.1    Ballantyne, C.M.2    Kastelein, J.J.3    Isaacsohn, J.L.4    Braeckman, R.A.5    Soni, P.N.6
  • 73
    • 77956165390 scopus 로고    scopus 로고
    • GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects
    • Oh da Y, Talukdar S, Bae EJ, et al., GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010; 142 (5): 687-98.
    • (2010) Cell , vol.142 , Issue.5 , pp. 687-698
    • Oh Da, Y.1    Talukdar, S.2    Bae, E.J.3
  • 74
    • 14744304497 scopus 로고    scopus 로고
    • Inhibition of triglyceride synthesis as a treatment strategy for obesity: Lessons from DGAT1-deficient mice
    • DOI 10.1161/01.ATV.0000151874.81059.ad
    • Chen HC, Farese RV Jr. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25 (3): 482-6. (Pubitemid 40330925)
    • (2005) Arteriosclerosis, Thrombosis, and Vascular Biology , vol.25 , Issue.3 , pp. 482-486
    • Chen, H.C.1    Farese Jr., R.V.2
  • 75
    • 77954896506 scopus 로고    scopus 로고
    • Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs
    • Le Bloc'h J, Leray V, Chetiveaux M, et al., Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs. J Pharmacol Exp Ther 2010; 334 (2): 583-9.
    • (2010) J Pharmacol Exp Ther , vol.334 , Issue.2 , pp. 583-589
    • Le Bloc'H, J.1    Leray, V.2    Chetiveaux, M.3
  • 77
    • 33845320131 scopus 로고    scopus 로고
    • Molecular regulation of HDL metabolism and function: Implications for novel therapies
    • DOI 10.1172/JCI30163
    • Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006; 116 (12): 3090-100. (Pubitemid 44878620)
    • (2006) Journal of Clinical Investigation , vol.116 , Issue.12 , pp. 3090-3100
    • Rader, D.J.1
  • 78
    • 70450081001 scopus 로고    scopus 로고
    • Major lipids, apolipoproteins, and risk of vascular disease
    • Di Angelantonio E, Sarwar N, Perry P, et al., Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302 (18): 1993-2000.
    • (2009) JAMA , vol.302 , Issue.18 , pp. 1993-2000
    • Di Angelantonio, E.1    Sarwar, N.2    Perry, P.3
  • 79
    • 11844296800 scopus 로고    scopus 로고
    • Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
    • DOI 10.1016/j.jacc.2004.10.031, PII S0735109704020625
    • Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45 (2): 185-97. (Pubitemid 40094724)
    • (2005) Journal of the American College of Cardiology , vol.45 , Issue.2 , pp. 185-197
    • Birjmohun, R.S.1    Hutten, B.A.2    Kastelein, J.J.P.3    Stroes, E.S.G.4
  • 80
    • 34047183679 scopus 로고    scopus 로고
    • CETP inhibitors to increase HDL cholesterol levels
    • DOI 10.1056/NEJMe078029
    • Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 2007; 356 (13): 1364-6. (Pubitemid 46513305)
    • (2007) New England Journal of Medicine , vol.356 , Issue.13 , pp. 1364-1366
    • Tall, A.R.1
  • 81
    • 0026026920 scopus 로고
    • Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin
    • Bisgaier CL, Siebenkas MV, Brown ML, et al., Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. J Lipid Res 1991; 32 (1): 21-33.
    • (1991) J Lipid Res , vol.32 , Issue.1 , pp. 21-33
    • Bisgaier, C.L.1    Siebenkas, M.V.2    Brown, M.L.3
  • 84
    • 58149380516 scopus 로고    scopus 로고
    • Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: A pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials
    • Vergeer M, Bots ML, van Leuven SI, et al., Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008; 118 (24): 2515-22.
    • (2008) Circulation , vol.118 , Issue.24 , pp. 2515-2522
    • Vergeer, M.1    Bots, M.L.2    Van Leuven, S.I.3
  • 85
    • 84984973611 scopus 로고    scopus 로고
    • Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
    • Barter PJ, Rye KA, Tardif JC, et al., Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011; 124 (5): 555-62.
    • (2011) Circulation , vol.124 , Issue.5 , pp. 555-562
    • Barter, P.J.1    Rye, K.A.2    Tardif, J.C.3
  • 86
    • 84863645713 scopus 로고    scopus 로고
    • Torcetrapib impairs endothelial function in hypertension
    • in press.
    • Simic B, Hermann M, Shaw SG, et al., Torcetrapib impairs endothelial function in hypertension. Eur Heart J 2011, in press.
    • (2011) Eur Heart J
    • Simic, B.1    Hermann, M.2    Shaw, S.G.3
  • 87
    • 77249100745 scopus 로고    scopus 로고
    • Safety and tolerability of dalcetrapib (RO4607381/JTT-705): Results from a 48-week trial
    • Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010; 31 (4): 480-8.
    • (2010) Eur Heart J , vol.31 , Issue.4 , pp. 480-488
    • Stein, E.A.1    Roth, E.M.2    Rhyne, J.M.3    Burgess, T.4    Kallend, D.5    Robinson, J.G.6
  • 88
    • 57849131140 scopus 로고    scopus 로고
    • Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia
    • Hermann F, Enseleit F, Spieker LE, et al., Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thromb Res 2009; 123 (3): 460-5.
    • (2009) Thromb Res , vol.123 , Issue.3 , pp. 460-465
    • Hermann, F.1    Enseleit, F.2    Spieker, L.E.3
  • 90
    • 80255122648 scopus 로고    scopus 로고
    • Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial
    • Fayad ZA, Mani V, Woodward M, et al., Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378 (9802): 1547-59.
    • (2011) Lancet , vol.378 , Issue.9802 , pp. 1547-1559
    • Fayad, Z.A.1    Mani, V.2    Woodward, M.3
  • 91
    • 70749131522 scopus 로고    scopus 로고
    • Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
    • Schwartz GG, Olsson AG, Ballantyne CM, et al., Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158 (6): 896-901.
    • (2009) Am Heart J , vol.158 , Issue.6 , pp. 896-901
    • Schwartz, G.G.1    Olsson, A.G.2    Ballantyne, C.M.3
  • 92
    • 78549235583 scopus 로고    scopus 로고
    • Safety of anacetrapib in patients with or at high risk for coronary heart disease
    • Cannon CP, Shah S, Dansky HM, et al., Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363 (25): 2406-15.
    • (2010) N Engl J Med , vol.363 , Issue.25 , pp. 2406-2415
    • Cannon, C.P.1    Shah, S.2    Dansky, H.M.3
  • 94
    • 81255125373 scopus 로고    scopus 로고
    • Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial
    • Nicholls SJ, Brewer HB, Kastelein JJ, et al., Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306 (19): 2099-109.
    • (2011) JAMA , vol.306 , Issue.19 , pp. 2099-2109
    • Nicholls, S.J.1    Brewer, H.B.2    Kastelein, J.J.3
  • 95
    • 84857322173 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetic and pharmacodynamic profile of multiple-doses of DRL-17822, a potent cholesteryl ester transfer protein inhibitor in healthy male subjects
    • A13981 [abstract].
    • Dasari MR, Bapat A, Vittal S, et al., Safety, tolerability, pharmacokinetic and pharmacodynamic profile of multiple-doses of DRL-17822, a potent cholesteryl ester transfer protein inhibitor in healthy male subjects. Circulation 2010; 122 (21 Suppl.): A13981 [abstract].
    • (2010) Circulation , vol.122 , Issue.21 SUPPL.
    • Dasari, M.R.1    Bapat, A.2    Vittal, S.3
  • 96
    • 0035992811 scopus 로고    scopus 로고
    • Glitazones: Clinical effects and molecular mechanisms
    • Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34 (3): 217-24. (Pubitemid 34804195)
    • (2002) Annals of Medicine , vol.34 , Issue.3 , pp. 217-224
    • Stumvoll, M.1    Haring, H.-U.2
  • 97
    • 34548580881 scopus 로고    scopus 로고
    • Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis
    • DOI 10.1001/jama.298.10.1189
    • Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298 (10): 1189-95. (Pubitemid 47403105)
    • (2007) Journal of the American Medical Association , vol.298 , Issue.10 , pp. 1189-1195
    • Singh, S.1    Loke, Y.K.2    Furberg, C.D.3
  • 99
    • 33745957332 scopus 로고    scopus 로고
    • Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study
    • DOI 10.2337/diacare.2951016
    • Kendall DM, Rubin CJ, Mohideen P, et al., Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006; 29 (5): 1016-23. (Pubitemid 44115238)
    • (2006) Diabetes Care , vol.29 , Issue.5 , pp. 1016-1023
    • Kendall, D.M.1    Rubin, C.J.2    Mohideen, P.3    Ledeine, J.-M.4    Belder, R.5    Gross, J.6    Norwood, P.7    O'Mahony, M.8    Sall, K.9    Sloan, G.10    Roberts, A.11    Fiedorek, F.T.12    DeFronzo, R.A.13
  • 100
    • 28144451163 scopus 로고    scopus 로고
    • Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
    • DOI 10.1001/jama.294.20.joc50147
    • Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294 (20): 2581-6. (Pubitemid 41697247)
    • (2005) Journal of the American Medical Association , vol.294 , Issue.20 , pp. 2581-2586
    • Nissen, S.E.1    Wolski, K.2    Topol, E.J.3
  • 101
    • 80051975559 scopus 로고    scopus 로고
    • Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting
    • Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34 (6): 1369-71.
    • (2011) Diabetes Care , vol.34 , Issue.6 , pp. 1369-1371
    • Piccinni, C.1    Motola, D.2    Marchesini, G.3    Poluzzi, E.4
  • 102
    • 67649839953 scopus 로고    scopus 로고
    • Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study
    • Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009; 374 (9684): 126-35.
    • (2009) Lancet , vol.374 , Issue.9684 , pp. 126-135
    • Henry, R.R.1    Lincoff, A.M.2    Mudaliar, S.3    Rabbia, M.4    Chognot, C.5    Herz, M.6
  • 104
    • 80053521381 scopus 로고    scopus 로고
    • Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-{delta} agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity
    • Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-{delta} agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab 2011; 96 (10): E1568-76.
    • (2011) J Clin Endocrinol Metab , vol.96 , Issue.10
    • Ooi, E.M.1    Watts, G.F.2    Sprecher, D.L.3    Chan, D.C.4    Barrett, P.H.5
  • 105
    • 79960988152 scopus 로고    scopus 로고
    • Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism
    • Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011; 34 (9): 2008-14.
    • (2011) Diabetes Care , vol.34 , Issue.9 , pp. 2008-2014
    • Cariou, B.1    Zair, Y.2    Staels, B.3    Bruckert, E.4
  • 106
    • 77952713824 scopus 로고    scopus 로고
    • RVX-208: A small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo
    • Bailey D, Jahagirdar R, Gordon A, et al., RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010; 55 (23): 2580-9.
    • (2010) J Am Coll Cardiol , vol.55 , Issue.23 , pp. 2580-2589
    • Bailey, D.1    Jahagirdar, R.2    Gordon, A.3
  • 107
    • 79952005101 scopus 로고    scopus 로고
    • Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial
    • Nicholls SJ, Gordon A, Johansson J, et al., Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol 2011; 57 (9): 1111-9.
    • (2011) J Am Coll Cardiol , vol.57 , Issue.9 , pp. 1111-1119
    • Nicholls, S.J.1    Gordon, A.2    Johansson, J.3
  • 109
    • 32044448047 scopus 로고    scopus 로고
    • Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano
    • Nicholls SJ, Tuzcu EM, Sipahi I, et al., Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006; 47 (5): 992-7.
    • (2006) J Am Coll Cardiol , vol.47 , Issue.5 , pp. 992-997
    • Nicholls, S.J.1    Tuzcu, E.M.2    Sipahi, I.3
  • 111
    • 0037154287 scopus 로고    scopus 로고
    • Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol
    • DOI 10.1161/hc0302.103711
    • Navab M, Anantharamaiah GM, Hama S, et al., Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105 (3): 290-2. (Pubitemid 34106174)
    • (2002) Circulation , vol.105 , Issue.3 , pp. 290-292
    • Navab, M.1    Anantharamaiah, G.M.2    Hama, S.3    Garber, D.W.4    Chaddha, M.5    Hough, G.6    Lallone, R.7    Fogelman, A.M.8
  • 112
    • 77952737056 scopus 로고    scopus 로고
    • A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice
    • Bielicki JK, Zhang H, Cortez Y, et al., A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 2010; 51 (6): 1496-503.
    • (2010) J Lipid Res , vol.51 , Issue.6 , pp. 1496-1503
    • Bielicki, J.K.1    Zhang, H.2    Cortez, Y.3
  • 114
    • 67649675003 scopus 로고    scopus 로고
    • Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo
    • Sacks FM, Rudel LL, Conner A, et al., Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 2009; 50 (5): 894-907.
    • (2009) J Lipid Res , vol.50 , Issue.5 , pp. 894-907
    • Sacks, F.M.1    Rudel, L.L.2    Conner, A.3
  • 115
    • 77953107241 scopus 로고    scopus 로고
    • A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome
    • Waksman R, Torguson R, Kent KM, et al., A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010; 55 (24): 2727-35.
    • (2010) J Am Coll Cardiol , vol.55 , Issue.24 , pp. 2727-2735
    • Waksman, R.1    Torguson, R.2    Kent, K.M.3
  • 116
    • 67651160488 scopus 로고    scopus 로고
    • Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target
    • Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol 2009; 24 (4): 358-63.
    • (2009) Curr Opin Cardiol , vol.24 , Issue.4 , pp. 358-363
    • Packard, C.J.1
  • 117
    • 54049152760 scopus 로고    scopus 로고
    • Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque
    • Serruys PW, Garcia-Garcia HM, Buszman P, et al., Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118 (11): 1172-82.
    • (2008) Circulation , vol.118 , Issue.11 , pp. 1172-1182
    • Serruys, P.W.1    Garcia-Garcia, H.M.2    Buszman, P.3
  • 120
    • 77956571375 scopus 로고    scopus 로고
    • Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients
    • Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol 2010; 56 (14): 1079-88.
    • (2010) J Am Coll Cardiol , vol.56 , Issue.14 , pp. 1079-1088
    • Rosenson, R.S.1    Hislop, C.2    Elliott, M.3    Stasiv, Y.4    Goulder, M.5    Waters, D.6
  • 121
    • 79954517998 scopus 로고    scopus 로고
    • Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease
    • Rosenson RS, Elliott M, Stasiv Y, Hislop C. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur Heart J 2011; 32 (8): 999-1005.
    • (2011) Eur Heart J , vol.32 , Issue.8 , pp. 999-1005
    • Rosenson, R.S.1    Elliott, M.2    Stasiv, Y.3    Hislop, C.4
  • 122
    • 78650711954 scopus 로고    scopus 로고
    • The sPLA2 inhibition to decrease enzyme release after percutaneous coronary intervention (SPIDER-PCI) trial
    • Dzavik V, Lavi S, Thorpe K, et al., The sPLA2 inhibition to decrease enzyme release after percutaneous coronary intervention (SPIDER-PCI) trial. Circulation 2010; 122 (23): 2411-8.
    • (2010) Circulation , vol.122 , Issue.23 , pp. 2411-2418
    • Dzavik, V.1    Lavi, S.2    Thorpe, K.3
  • 126
    • 65949115488 scopus 로고    scopus 로고
    • Ex vivo liver-directed gene therapy for the treatment of metabolic diseases: Advances in hepatocyte transplantation and retroviral vectors
    • Nguyen TH, Mainot S, Lainas P, et al., Ex vivo liver-directed gene therapy for the treatment of metabolic diseases: advances in hepatocyte transplantation and retroviral vectors. Curr Gene Ther 2009; 9 (2): 136-49.
    • (2009) Curr Gene Ther , vol.9 , Issue.2 , pp. 136-149
    • Nguyen, T.H.1    Mainot, S.2    Lainas, P.3
  • 128
    • 77952571307 scopus 로고    scopus 로고
    • Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency
    • Gaudet D, de WJ, Tremblay K, et al., Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010; 11 (1): 55-60.
    • (2010) Atheroscler Suppl , vol.11 , Issue.1 , pp. 55-60
    • Gaudet, D.1    De, W.J.2    Tremblay, K.3
  • 129
    • 72449205978 scopus 로고    scopus 로고
    • AAV1-LPLS447X gene therapy with alipogene tiparvovec prevents pancreatitis in lipoprotein lipase deficiency
    • [abstract].
    • Franssen R, Gaudet D, Stroes ES, et al., AAV1-LPLS447X gene therapy with alipogene tiparvovec prevents pancreatitis in lipoprotein lipase deficiency. Circulation 2009; 120 (Suppl.): S591-2 [abstract].
    • (2009) Circulation , vol.120 , Issue.SUPPL.
    • Franssen, R.1    Gaudet, D.2    Stroes, E.S.3
  • 130
    • 84857354344 scopus 로고    scopus 로고
    • Gene therapy with alipogene tiparvovec results in enhanced post-prandial clearance of low density chylomicrons in LPLD patients
    • A16900 [abstract].
    • Carpentier A, Frisch F, Labbe SM, et al., Gene therapy with alipogene tiparvovec results in enhanced post-prandial clearance of low density chylomicrons in LPLD patients. Circulation 2010; 122 (21 Suppl.): A16900 [abstract].
    • (2010) Circulation , vol.122 , Issue.21 SUPPL.
    • Carpentier, A.1    Frisch, F.2    Labbe, S.M.3
  • 131
    • 84896377625 scopus 로고    scopus 로고
    • Modifications in triglyceride-rich lipoprotein metabolism induced by alipogene tiparvovec (AAV1-LPLS447X Gene Therapy) correlate with clinical benefit in patients with lipoprotein lipase deficiency (LPLD)
    • A21355 [abstract].
    • Gaudet D, Methot J, Gagne C, et al., Modifications in triglyceride-rich lipoprotein metabolism induced by alipogene tiparvovec (AAV1-LPLS447X Gene Therapy) correlate with clinical benefit in patients with lipoprotein lipase deficiency (LPLD). Circulation 2010; 122 (21 Suppl.): A21355 [abstract].
    • (2010) Circulation , vol.122 , Issue.21 SUPPL.
    • Gaudet, D.1    Methot, J.2    Gagne, C.3
  • 132
    • 77954643491 scopus 로고    scopus 로고
    • A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors
    • Malekzadeh F, Marshall T, Pourshams A, et al., A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract 2010; 64 (9): 1220-7.
    • (2010) Int J Clin Pract , vol.64 , Issue.9 , pp. 1220-1227
    • Malekzadeh, F.1    Marshall, T.2    Pourshams, A.3
  • 133
    • 64349095030 scopus 로고    scopus 로고
    • Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial
    • Yusuf S, Pais P, Afzal R, et al., Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373 (9672): 1341-51.
    • (2009) Lancet , vol.373 , Issue.9672 , pp. 1341-1351
    • Yusuf, S.1    Pais, P.2    Afzal, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.